Prosecution Insights
Last updated: April 19, 2026
Application No. 18/263,826

PHEROMONE DIFFUSING GEL

Non-Final OA §102§103§112
Filed
Aug 01, 2023
Examiner
VU, JAKE MINH
Art Unit
1618
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Virbac
OA Round
1 (Non-Final)
40%
Grant Probability
Moderate
1-2
OA Rounds
4y 1m
To Grant
68%
With Interview

Examiner Intelligence

Grants 40% of resolved cases
40%
Career Allow Rate
318 granted / 787 resolved
-19.6% vs TC avg
Strong +28% interview lift
Without
With
+27.5%
Interview Lift
resolved cases with interview
Typical timeline
4y 1m
Avg Prosecution
40 currently pending
Career history
827
Total Applications
across all art units

Statute-Specific Performance

§101
0.4%
-39.6% vs TC avg
§103
39.9%
-0.1% vs TC avg
§102
22.6%
-17.4% vs TC avg
§112
21.6%
-18.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 787 resolved cases

Office Action

§102 §103 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Receipt is acknowledged of Applicant’s Restriction Requirement Response filed on 12/05/2025; and IDS filed on 11/27/2024 and 08/01/2023. Claims 1-20 are pending in the instant application. Claims 8-15 are withdrawn from further consideration. Election/Restrictions Applicant's election with traverse of Group I (claims 1-7, 16-20) in the reply filed on 12/05/2025 is acknowledged. The traversal is on the ground(s) that portable diffuser claim 8 of Group (II) and method claim 12 of Group (III) are each explicitly dependent on claim 1 and requires all the limitations of the product claim 1, and claims 9-11 and 13-15 are explicitly dependent directly or indirectly on claim 8 or claim 12, respectively. Accordingly, current claims 8-11 of Group (I) and claims 12-15 of Group (II) with explicit dependency on claim 1 of the elected Group (I) have unity of invention with the claims of the elected Group (I). Whether the product of claim 1 may be obtained by different methods or from different sources, or whether it may be used in different ways for different purposes, are irrelevant to the "unity of invention" inquiry under PCT rules. In summary, a common or corresponding special technical feature is present in that the respective subject matter of the pending claims, so the present claims comply with "unity of invention" rules. This is not found persuasive because, as discussed in the restriction requirement, the inventions lack unity of invention because even though the inventions of these groups require the technical feature of claim 1, this technical feature is not a special technical feature as it does not make a contribution over the prior art. The requirement is still deemed proper and is therefore made FINAL. Claim Rejections - 35 USC § 112, 2nd paragraph The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-4, 6, 16-20 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. The term "volatile fatty acid derivatives" in claim 1, renders the scope of said claim unclear since, on reading the document, a person skilled in the art would not know which structures are supposed to be encompassed by this term. The term "derivatives" encompasses compounds obtained by chemical reaction from another compound, including compounds of which the structure is far removed from the starting element, functional derivatives (such as compounds in which the heteroatoms are replaced by other atoms), compounds comprising numerous different types of side groups, etc. For examination purposes, any fatty acid will read on this term. Note, every fatty acids are volatile to a certain degree. The dependent claims fall therewith. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1, 3-4, 16-19 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by BAR-SHALOM et al (US 2008/0299199). BAR-SHALOM teaches a composition that can swell and forms a gel (see abstract) comprised of: gellan gum (see abstract), which is a polysaccharide and would form the polysaccharide gel matrix; active agents, such as fatty acids (see [0120]) and fish oils, which has fatty acids and reads on volatile fatty acid derivatives; solubilizers (see [0075]), such as ethanol (see [0287]); and organic acids (see [0067]), such as citric acid for pH-adjusting (see [0062]). Additional disclosures include: preservatives, coloring agents (see [0075]) and bases (see [0075]), which are bitter in taste. Note, fatty acids are volatile to a certain degree. For examination purposes, any fatty acid will read on volatile fatty acid derivatives. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 1-2, 4-6, 16-20 is/are rejected under 35 U.S.C. 103 as being unpatentable over BAR-SHALOM et al (US 2008/0299199). As discussed above, BAR-SHALOM teaches a composition that can swell and forms a gel (see abstract) comprised of: gellan gum (see abstract), which is a polysaccharide and would form the polysaccharide gel matrix; active agents, such as fatty acids (see [0120]) and fish oils, which has fatty acids and reads on volatile fatty acid derivatives; solubilizers (see [0075]), such as ethanol (see [0287]); and organic acids (see [0067]), such as citric acid for pH-adjusting (see [0062]). Additional disclosures include: preservatives, coloring agents (see [0075]) and bases (see [0075]), which are bitter in taste. Note, fatty acids are volatile to a certain degree. For examination purposes, any fatty acid will read on volatile fatty acid derivatives. The reference does not specifically teach adding the ingredients in the amounts claimed by Applicant. The amount of a specific ingredient in a composition is clearly a result effective parameter that a person of ordinary skill in the art would routinely optimize. Optimization of parameters is a routine practice that would be obvious for a person of ordinary skill in the art to employ and reasonably would expect success. It would have been customary for an artisan of ordinary skill to determine the optimal amount of each ingredient to add in order to best achieve the desired results, such as solubilizing active agents, adjusting to the desired pH, etc. Thus, absent some demonstration of unexpected results from the claimed parameters, this optimization of ingredient amount would have been obvious at the time of Applicant's invention. Allowable Subject Matter Claims 5 and 7 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Telephonic Inquiries Any inquiry concerning this communication or earlier communications from the examiner should be directed to JAKE MINH VU whose telephone number is (571)272-8148. The examiner can normally be reached Mon-Fri 9:00am-5:30pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Michael Hartley can be reached at (571) 272-0616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JAKE M VU/Primary Examiner, Art Unit 1618
Read full office action

Prosecution Timeline

Aug 01, 2023
Application Filed
Mar 30, 2026
Non-Final Rejection — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12594245
Dry Powder Formulations for Messenger RNA
2y 5m to grant Granted Apr 07, 2026
Patent 12584173
METHODS FOR DISEASE TREATMENT AND DRUG DISCOVERY
2y 5m to grant Granted Mar 24, 2026
Patent 12582615
TOPICAL ANALGESIC GEL COMPOSITIONS
2y 5m to grant Granted Mar 24, 2026
Patent 12582676
Hydrogel Particle Encapsulated Viable Cells for In Vivo Regenerative Treatment
2y 5m to grant Granted Mar 24, 2026
Patent 12576169
SILICON-FLUORIDE ACCEPTOR SUBSTITUTED RADIOPHARMACEUTICALS AND PRECURSORS THEREOF
2y 5m to grant Granted Mar 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
40%
Grant Probability
68%
With Interview (+27.5%)
4y 1m
Median Time to Grant
Low
PTA Risk
Based on 787 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month